OrbiMed, a global healthcare investor, closed its third Asia private equity fund with $551 million in capital commitments, about $100 million more than the target listed in its initial filing six months ago. OrbiMed Asia Partners III will consider investments in all parts of Asia healthcare, but it expects to focus on growth-stage product and service companies in China and India. The Fund plans to make 15-20 investments that range from $10 to $75 million each. OrbiMed’s two previous Asia funds totaled slightly less than $500 million.
Source: China Biotoday
